Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics

NCT00739752
Conditions
Hepatitis B Virus
Interventions
Non-Framed-Offered, Non-Framed-Recommended, Gain-Framed-Offered, Gain-Framed-Recommended, Loss-Framed-Offered, Loss-Framed-Recommended
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1,747 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
2
States / cities
Chicago, Illinois • Indianapolis, Indiana
Completed Phase 1Phase 2 Interventional Results available

The Effect of Ixazomib on the Latent HIV Reservoir

NCT02946047
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Ixazomib 1 MG, Ixazomib 2 MG, Ixazomib 3 MG, Ixazomib 4 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Morristown, New Jersey
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the ViSiGiTM Calibration System

NCT02008825
Conditions
Enhance Delineation of the Stomach Anatomy and the Surgeon's Appreciation of the Extent of Gastric Volume to be Removed;, Increase the Safety Profile of the Patient (i.e., Reduce the Likelihood of Accidental Stapling of the Orogastric Tube or Bougie);, Reduce the Incidence of OR Contamination/Infection Transmission;, Streamline OR Workflow, Resulting in Reduced OR Time, Ensure Consistent and Reproducible Staple Lines.
Interventions
Utilization of ViSiGi calibration tube, Usual non suction Bougie
Device
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Allentown, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

NCT00110591
Conditions
HIV Infections
Interventions
PRO 140
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
HIV Infections, Tuberculosis
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
14
States / cities
New Haven, Connecticut • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more
Not listed Not applicable Interventional Accepts healthy volunteers

Contraceptive Awareness and Reproductive Education

NCT01132950
Conditions
Contraception, Sexually Transmitted Diseases, Pregnancy
Interventions
Motivational Interviewing, Didactic Educational Counseling
Behavioral · Other
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Three Experimental HIV Vaccines

NCT00000946
Conditions
HIV Infections, HIV Seronegativity
Interventions
HIV p24/MF59 Vaccine, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Diego, California
Conditions
Human Immunodeficiency Virus (HIV), Self-efficacy, Self-esteem
Interventions
Ipod video
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Henderson, North Carolina
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Conditions
Opiate Dependence, HIV Seropositivity, HIV Infections
Interventions
Clinic-based substance abuse treatment with buprenorphine, Case management and referred substance abuse treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Not listed No phase listed Observational Accepts healthy volunteers

Transgender Cohort Study of Gender Affirmation and HIV-related Health

NCT03595956
Conditions
HIV/AIDS, STI, Gender Dysphoria, Transsexualism, Gender Identity, Depression, Anxiety
Interventions
Medical gender affirmation
Other
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV

NCT01407237
Conditions
HIV-infection
Interventions
Angiotensin II Infusion
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
3
States / cities
Los Angeles, California • Miami, Florida • Memphis, Tennessee
Conditions
Healthy Subject, Human Papillomavirus Infection
Interventions
carrageenan-containing gel, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
19 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
HIV Infections
Interventions
GW695634
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Francisco, California + 15 more
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Wilmington, North Carolina
Conditions
HIV Infections
Interventions
Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Completed Phase 1Phase 2 Interventional Results available

AIDS 347: IL-6 Blockade in Treated HIV Infection

NCT02049437
Conditions
HIV Infections
Interventions
tocilizumab, Placebo
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)

NCT06498661
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 11 more
Conditions
Dyslipidemias, Cardiovascular Diseases, HIV Infections
Interventions
Alirocumab, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
San Francisco, California
Completed Not applicable Interventional Results available

Smoking Cessation Using Motivational Therapy and Varenicline

NCT00701896
Conditions
Smoking, HIV Infections
Interventions
Varenicline tartrate, Nicotine Replacement Therapy, Biological Control, Motivational Interview
Drug · Other · Behavioral
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas